

# MNKD Products & Pipeline



Product	Targeted Indications	Pre-IND	Phase 1	Phase 2	Phase 3	Approval
<b>Afrezza® (insulin human) Inhalation Powder</b>	T1DM / T2DM (adults)					Marketed
	T1DM / T2DM (pediatrics)				PDUFA: Q2 2026	
<b>V-Go® All-in-One Insulin Delivery Patch</b>	T1DM / T2DM (adults)					Marketed
<b>FUROSCIX® (furosemide injection)</b> (marketed by scPharmaceuticals, a wholly owned subsidiary of MannKind)	Edema from CHF / CKD					Marketed
<b>FUROSCIX ReadyFlow™ Autoinjector</b>	Edema from CHF / CKD				PDUFA: Q3 2026	
<b>Bumetanide DPI</b> (MNKD-701)	Edema from CHF / CKD	Pre-Clinical				
<b>Tyvaso DPI® (treprostinil) Inhalation Powder</b> (marketed by United Therapeutics)	PAH / PH-ILD					Marketed
<b>Nintedanib DPI</b> (MNKD-201)	IPF			Phase 2 (INFLO-2 study)		
<b>Clofazimine DPI</b> (MNKD-102)	NTM	Pre-Clinical				
<b>Partner Program with United Therapeutics</b> (MNKD-1501)	UNDISCLOSED	STAGE UNDISCLOSED				